Sarcopenia Screened With SARC-F Questionnaire Is Associated With Quality of Life and 4-Year Mortality

Tai Yin Wu, Chen Kun Liaw, Fang Chun Chen, Kuan Liang Kuo, Wei Chu Chie, Rong Sen Yang

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objectives There is no gold standard in diagnosing sarcopenia. We aimed to assess the validity of screening sarcopenia using SARC-F (sluggishness, assistance in walking, rise from a chair, climb stairs, falls). Design Prospective cohort study. Setting Community hospital in Taiwan. Participants Community-dwelling senior citizens. Measurements Participants were interviewed with a structured questionnaire annually. The questionnaire items were recoded into the 5 items of SARC-F (sluggishness, assistance in walking, rise from a chair, climb stairs, falls). In the baseline year, a subgroup was tested for grip strength and body composition. Healthcare utilization and mortality were based on self-report and hospital records. Our main outcome was 4-year mortality. Secondary outcomes included hospitalization, emergency care use, and quality of life (QOL) measured using the CASP-12 scale (control, autonomy, self-realization, pleasure (control, autonomy, self-realization, pressure). Results There were 670 participants. The mean age was 76.1 (standard deviation 6.36). One-half were men (n = 340, 50.7%). The prevalence of sarcopenia was 6.1% (n = 41). SARC-F scores were inversely associated with grip strength (P = .001) and skeletal muscle composition (P = .045). Participants with sarcopenia were mostly women (P = .005) and older (P < .001). In univariate analysis, sarcopenia was associated with 1- to 4-year mortalities (P = .033, .001, .001, <.001, respectively), overall hospitalization (P = .004), overall emergency care use (P = .017), and QOL (P < .001). In multivariate model, sarcopenia [odds ratio (OR) 7.35, 95% confidence interval (CI) 2.67-20.18], age (OR 1.19, 95% CI 1.09-1.29 for each year), and taking vitamin D supplements (OR 0.29, 95% CI 0.11-0.74) were factors associated with mortality. Conclusions Sarcopenia screened using SARC-F was associated with subsequent QOL, overall hospitalization, overall emergency care use, and 4-year mortality. SARC-F can serve as a quick screening tool of sarcopenia.

Original languageEnglish
Pages (from-to)1129-1135
Number of pages7
JournalJournal of the American Medical Directors Association
Volume17
Issue number12
DOIs
Publication statusPublished - Dec 1 2016
Externally publishedYes

Fingerprint

Sarcopenia
Quality of Life
Mortality
Emergency Medical Services
Hospitalization
Odds Ratio
Hand Strength
Confidence Intervals
Walking
Independent Living
Pleasure
Surveys and Questionnaires
Hospital Records
Community Hospital
Body Composition
Taiwan
Vitamin D
Self Report
Skeletal Muscle
Cohort Studies

Keywords

  • mortality
  • SARC-F
  • Sarcopenia

ASJC Scopus subject areas

  • Nursing(all)
  • Health Policy

Cite this

Sarcopenia Screened With SARC-F Questionnaire Is Associated With Quality of Life and 4-Year Mortality. / Wu, Tai Yin; Liaw, Chen Kun; Chen, Fang Chun; Kuo, Kuan Liang; Chie, Wei Chu; Yang, Rong Sen.

In: Journal of the American Medical Directors Association, Vol. 17, No. 12, 01.12.2016, p. 1129-1135.

Research output: Contribution to journalArticle

Wu, Tai Yin ; Liaw, Chen Kun ; Chen, Fang Chun ; Kuo, Kuan Liang ; Chie, Wei Chu ; Yang, Rong Sen. / Sarcopenia Screened With SARC-F Questionnaire Is Associated With Quality of Life and 4-Year Mortality. In: Journal of the American Medical Directors Association. 2016 ; Vol. 17, No. 12. pp. 1129-1135.
@article{74b38c9655da4ea3962ce0b71c724fa4,
title = "Sarcopenia Screened With SARC-F Questionnaire Is Associated With Quality of Life and 4-Year Mortality",
abstract = "Objectives There is no gold standard in diagnosing sarcopenia. We aimed to assess the validity of screening sarcopenia using SARC-F (sluggishness, assistance in walking, rise from a chair, climb stairs, falls). Design Prospective cohort study. Setting Community hospital in Taiwan. Participants Community-dwelling senior citizens. Measurements Participants were interviewed with a structured questionnaire annually. The questionnaire items were recoded into the 5 items of SARC-F (sluggishness, assistance in walking, rise from a chair, climb stairs, falls). In the baseline year, a subgroup was tested for grip strength and body composition. Healthcare utilization and mortality were based on self-report and hospital records. Our main outcome was 4-year mortality. Secondary outcomes included hospitalization, emergency care use, and quality of life (QOL) measured using the CASP-12 scale (control, autonomy, self-realization, pleasure (control, autonomy, self-realization, pressure). Results There were 670 participants. The mean age was 76.1 (standard deviation 6.36). One-half were men (n = 340, 50.7{\%}). The prevalence of sarcopenia was 6.1{\%} (n = 41). SARC-F scores were inversely associated with grip strength (P = .001) and skeletal muscle composition (P = .045). Participants with sarcopenia were mostly women (P = .005) and older (P < .001). In univariate analysis, sarcopenia was associated with 1- to 4-year mortalities (P = .033, .001, .001, <.001, respectively), overall hospitalization (P = .004), overall emergency care use (P = .017), and QOL (P < .001). In multivariate model, sarcopenia [odds ratio (OR) 7.35, 95{\%} confidence interval (CI) 2.67-20.18], age (OR 1.19, 95{\%} CI 1.09-1.29 for each year), and taking vitamin D supplements (OR 0.29, 95{\%} CI 0.11-0.74) were factors associated with mortality. Conclusions Sarcopenia screened using SARC-F was associated with subsequent QOL, overall hospitalization, overall emergency care use, and 4-year mortality. SARC-F can serve as a quick screening tool of sarcopenia.",
keywords = "mortality, SARC-F, Sarcopenia",
author = "Wu, {Tai Yin} and Liaw, {Chen Kun} and Chen, {Fang Chun} and Kuo, {Kuan Liang} and Chie, {Wei Chu} and Yang, {Rong Sen}",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.jamda.2016.07.029",
language = "English",
volume = "17",
pages = "1129--1135",
journal = "Journal of the American Medical Directors Association",
issn = "1525-8610",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Sarcopenia Screened With SARC-F Questionnaire Is Associated With Quality of Life and 4-Year Mortality

AU - Wu, Tai Yin

AU - Liaw, Chen Kun

AU - Chen, Fang Chun

AU - Kuo, Kuan Liang

AU - Chie, Wei Chu

AU - Yang, Rong Sen

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Objectives There is no gold standard in diagnosing sarcopenia. We aimed to assess the validity of screening sarcopenia using SARC-F (sluggishness, assistance in walking, rise from a chair, climb stairs, falls). Design Prospective cohort study. Setting Community hospital in Taiwan. Participants Community-dwelling senior citizens. Measurements Participants were interviewed with a structured questionnaire annually. The questionnaire items were recoded into the 5 items of SARC-F (sluggishness, assistance in walking, rise from a chair, climb stairs, falls). In the baseline year, a subgroup was tested for grip strength and body composition. Healthcare utilization and mortality were based on self-report and hospital records. Our main outcome was 4-year mortality. Secondary outcomes included hospitalization, emergency care use, and quality of life (QOL) measured using the CASP-12 scale (control, autonomy, self-realization, pleasure (control, autonomy, self-realization, pressure). Results There were 670 participants. The mean age was 76.1 (standard deviation 6.36). One-half were men (n = 340, 50.7%). The prevalence of sarcopenia was 6.1% (n = 41). SARC-F scores were inversely associated with grip strength (P = .001) and skeletal muscle composition (P = .045). Participants with sarcopenia were mostly women (P = .005) and older (P < .001). In univariate analysis, sarcopenia was associated with 1- to 4-year mortalities (P = .033, .001, .001, <.001, respectively), overall hospitalization (P = .004), overall emergency care use (P = .017), and QOL (P < .001). In multivariate model, sarcopenia [odds ratio (OR) 7.35, 95% confidence interval (CI) 2.67-20.18], age (OR 1.19, 95% CI 1.09-1.29 for each year), and taking vitamin D supplements (OR 0.29, 95% CI 0.11-0.74) were factors associated with mortality. Conclusions Sarcopenia screened using SARC-F was associated with subsequent QOL, overall hospitalization, overall emergency care use, and 4-year mortality. SARC-F can serve as a quick screening tool of sarcopenia.

AB - Objectives There is no gold standard in diagnosing sarcopenia. We aimed to assess the validity of screening sarcopenia using SARC-F (sluggishness, assistance in walking, rise from a chair, climb stairs, falls). Design Prospective cohort study. Setting Community hospital in Taiwan. Participants Community-dwelling senior citizens. Measurements Participants were interviewed with a structured questionnaire annually. The questionnaire items were recoded into the 5 items of SARC-F (sluggishness, assistance in walking, rise from a chair, climb stairs, falls). In the baseline year, a subgroup was tested for grip strength and body composition. Healthcare utilization and mortality were based on self-report and hospital records. Our main outcome was 4-year mortality. Secondary outcomes included hospitalization, emergency care use, and quality of life (QOL) measured using the CASP-12 scale (control, autonomy, self-realization, pleasure (control, autonomy, self-realization, pressure). Results There were 670 participants. The mean age was 76.1 (standard deviation 6.36). One-half were men (n = 340, 50.7%). The prevalence of sarcopenia was 6.1% (n = 41). SARC-F scores were inversely associated with grip strength (P = .001) and skeletal muscle composition (P = .045). Participants with sarcopenia were mostly women (P = .005) and older (P < .001). In univariate analysis, sarcopenia was associated with 1- to 4-year mortalities (P = .033, .001, .001, <.001, respectively), overall hospitalization (P = .004), overall emergency care use (P = .017), and QOL (P < .001). In multivariate model, sarcopenia [odds ratio (OR) 7.35, 95% confidence interval (CI) 2.67-20.18], age (OR 1.19, 95% CI 1.09-1.29 for each year), and taking vitamin D supplements (OR 0.29, 95% CI 0.11-0.74) were factors associated with mortality. Conclusions Sarcopenia screened using SARC-F was associated with subsequent QOL, overall hospitalization, overall emergency care use, and 4-year mortality. SARC-F can serve as a quick screening tool of sarcopenia.

KW - mortality

KW - SARC-F

KW - Sarcopenia

UR - http://www.scopus.com/inward/record.url?scp=84994481829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994481829&partnerID=8YFLogxK

U2 - 10.1016/j.jamda.2016.07.029

DO - 10.1016/j.jamda.2016.07.029

M3 - Article

C2 - 27666334

AN - SCOPUS:84994481829

VL - 17

SP - 1129

EP - 1135

JO - Journal of the American Medical Directors Association

JF - Journal of the American Medical Directors Association

SN - 1525-8610

IS - 12

ER -